Overview

Lot-to-Lot Consistency of V114 in Healthy Adults (V114-020)

Status:
Completed
Trial end date:
2020-04-03
Target enrollment:
Participant gender:
Summary
The primary objectives are to evaluate the safety and tolerability of V114 and to compare the serotype-specific opsonophagocytic activity (OPA) geometric mean titers (GMTs) across 3 different lots of V114. The primary hypothesis is that all 3 lots of V114 are equivalent as measured by the serotype-specific OPA GMTs for 15 serotypes in V114 at 30 days postvaccination.
Phase:
Phase 3
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.
Treatments:
Heptavalent Pneumococcal Conjugate Vaccine
Vaccines